Navigation Links
Investigational Diabetes Drug May Also Have Future As Treatment for Parkinson's Disease
Date:9/19/2013

KALAMAZOO, Mich., Sept. 19, 2013 /PRNewswire/ -- Metabolic Solutions Development Company, LLC (MSDC) announced today the presentation of new data showing an investigational drug being studied to treat diabetes, MSDC-0160, had a protective effect  on nerve cells in the brain that control movement, balance and walking.  These results in laboratory and animal models of Parkinson's disease suggest MSDC-0160 may have the potential to modify the course of Parkinson's disease. The Company is preparing for the start of clinical trials, which could begin in late 2014.

These results were generated in collaboration with Patrik Brundin, MD, PhD, Head of the Laboratory of Translational Parkinson's Disease Research and Director of the Center for Neurodegenerative Science at the Van Andel Institute (VAI). The data were presented by post-doctoral fellow Anamitra Ghosh at the "Grand Challenges in Parkinson's Disease" symposium, which is being convened September 18 – 19 at VAI (Grand Rapids, MI).

First in Class
MSDC-0160 is the first in a new class of insulin sensitizers called mTOT Modulators™, which appear to exert their therapeutic effects through a new drug target located in the inner mitochondrial membrane. MSDC-0160 has been shown to be well-tolerated and no significant safety issues were noted in studies in patients with type 2 diabetes or elderly patients with dementia due to Alzheimer's disease. In a Phase 2b clinical trial in 258 patients with type 2 diabetes, MSDC-0160 was shown to lower hemoglobin A1c significantly without the side effect profile of currently marketed insulin sensitizers, which are PPARg agonists. In a recently completed Phase 2a trial in 29 patients with dementia due to Alzheimer's disease (NCT01374438), MSDC-0160 was shown to maintain or increase glucose metabolism in the brain, as measured by FDG-PET imaging, in predefined regions of interest in the brain associated with cognitive decline.

Mitochondria and Parkinson's Disease
Parkinson's disease is a chronic, degenerative neurological disorder that affects an estimated one million people in the United States, and more than five million worldwide. Impaired mitochondrial function has been implicated in the development of Parkinson's disease. Mitochondria are the "power plants" of the cell, generating energy needed for cell activity. Therapies that improve mitochondrial function may have the potential to slow the progression of the disease.

About Metabolic Solutions Development Company
Metabolic Solutions Development Company (www.msdrx.com) is a drug discovery and development company investigating novel molecular targets and developing new therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially type 2 diabetes.

About Van Andel Institute
Established by Jay and Betty Van Andel in 1996, Van Andel Institute is an independent research organization dedicated to preserving, enhancing and expanding the frontiers of medical science, and to achieving excellence in education by probing fundamental issues of education and the learning process. This is accomplished through the work of over 200 researchers in more than 20 on-site laboratories and in collaborative partnerships that span the globe. Find out more about Van Andel Institute or donate by visiting www.vai.org

About Patrik Brundin, MD, PhD
Patrik Brundin, M.D., Ph.D. Brundin has more than 30 years of experience with neurodegenerative diseases, Parkinson's disease pathogenesis, and therapeutic neural grafting into people with Parkinson's disease. He is one of the top cited researchers in the field of neuroscience with around 300 publications on Parkinson's disease and related topics. In addition to managing laboratories at VAI and at Lund University, Sweden, he is the co-editor in chief of the Journal of Parkinson's Disease and has coordinated multiple international research programs.  


'/>"/>
SOURCE Metabolic Solutions Development Company, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Lillys Investigational GLP-1 Receptor Agonist, Dulaglutide, Showed Superior Glycemic Control Versus Comparators in Patients with Type 2 Diabetes
2. AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting
3. Oramed Pharmaceuticals Moves Forward with Investigational New Drug Application for Oral Insulin
4. Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
5. Upsher-Smith Currently Recruiting People With Epilepsy To Evaluate Investigational Rescue Treatment For Seizure Clusters
6. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
7. Oramed Submits Pre-IND Package to FDA for ORMD-0901 (oral exenatide), an Oral GLP-1 Analog for the Treatment of Type 2 Diabetes
8. ImmusanT Initiates Study at Joslin Diabetes Center to Investigate Relationship Between Celiac Disease and Type 1 Diabetes
9. Islet Sciences, Inc. Technologies Featured in Five Separate Presentations at the American Diabetes Association Annual Meeting
10. Results of new exploratory analyses assessing the incidence of hypoglycemia with linagliptin in adults with type 2 diabetes announced
11. Research Report on Chinas Diabetes Drug Market, 2013-2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... ... program has won a US2020 STEM Mentoring Award. Representatives of the FirstHand program ... in Volunteer Experience from US2020. , US2020’s mission is to change the trajectory ...
(Date:10/10/2017)... CALIFORNIA (PRWEB) , ... October 10, 2017 , ... ... technological innovation and business process optimization firm for the life sciences and healthcare ... BoxWorks conference in San Francisco. , The presentation, “Automating GxP Validation for ...
(Date:10/9/2017)... ... 09, 2017 , ... At its national board meeting in North Carolina, ... University’s Departments of Physics and Astronomy, has been selected for membership in ARCS ... for the 2015 Breakthrough Prize in Fundamental physics for the discovery of the accelerating ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available ... bioinformatics software to perform Hi-C metagenome deconvolution using their own facilities, supplementing ...
Breaking Biology Technology:
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
(Date:3/28/2017)... The report "Video Surveillance Market ... Storage Devices), Software (Video Analytics, VMS), and Service (VSaaS, ... to 2022", published by MarketsandMarkets, the market was valued ... to reach USD 75.64 Billion by 2022, at a ... year considered for the study is 2016 and the ...
(Date:3/24/2017)... -- The Controller General of Immigration from Maldives Mr. ... have received the prestigious international IAIR Award for the most innovative high ... ... Maldives Immigration Controller ... (small picture on the right) have received the IAIR award for the ...
Breaking Biology News(10 mins):